Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cryo-Cell International ( (CCEL) ) has issued an update.
Cryo-Cell International, Inc. has received a notice of termination from Duke University regarding their Patent and Technology License Agreement, effective May 17, 2025. The termination is based on Duke’s claim that Cryo-Cell breached the agreement, following Cryo-Cell’s arbitration demand alleging fraudulent inducement and multiple breaches by Duke.
The most recent analyst rating on (CCEL) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Cryo-Cell International stock, see the CCEL Stock Forecast page.
Spark’s Take on CCEL Stock
According to Spark, TipRanks’ AI Analyst, CCEL is a Neutral.
Cryo-Cell International’s overall stock score is impacted by moderate financial performance, highlighted by strong cash flow but significant balance sheet issues, including negative equity. The technical analysis indicates a bearish trend, which, combined with overvaluation concerns, further pressures the stock. The recent decision to reduce the dividend signals cautious financial management, contributing to a lower score.
To see Spark’s full report on CCEL stock, click here.
More about Cryo-Cell International
Cryo-Cell International, Inc. operates in the biotechnology industry, focusing on the collection and storage of umbilical cord blood and tissue for potential future medical use.
Average Trading Volume: 13,206
Technical Sentiment Signal: Sell
Current Market Cap: $42.35M
For a thorough assessment of CCEL stock, go to TipRanks’ Stock Analysis page.